CoChat

Familial ALS/FTD-associated RNA-binding deficient TDP-43 mutants cause neuronal and synaptic transcript dysregulation in vitro

Open access
Magarotto, Molly, Gawne, Richard T, Vilkaite, Gabriele, Beltrami, Marcello, Mason, Andrew S, Chen, Han-Jou · 2025 · Human Molecular Genetics

Published version of a preprint

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index; none of the 84 sources its claims cite is checked for support yet.

Abstract

TDP-43 is an RNA-binding protein constituting the pathological inclusions observed in ~ 95% of ALS and ~ 50% of FTD patients. In ALS and FTD, TDP-43 mislocalises to the cytoplasm and forms insoluble, hyperphosphorylated and ubiquitinated aggregates that enhance cytotoxicity and contribute to neurodegeneration. Despite its primary role as an RNA/DNA-binding protein, how RNA-binding deficiencies contribute to disease onset and progression are little understood. Among many identified familial mutations in TDP-43 causing ALS/FTD, only two mutations cause an RNA-binding deficiency, K181E and K263E. In this study, we used CRISPR/Cas9 to knock-in the two disease-linked RNA-binding deficient mutations in SH-SY5Y cells, generating both homozygous and heterozygous versions of the mutant TDP-43 to investigate TDP-43-mediated neuronal disruption. Significant changes were identified in the transcriptomic profiles of these cells, in particular, between K181E homozygous and heterozygous cells, with the most affected genes involved in neuronal differentiation and synaptic pathways. This result was validated in cell studies where the neuronal differentiation efficiency and neurite morphology were compromised in TDP-43 cells compared to unmodified control. Interestingly, divergent neuronal regulation was observed in K181E-TDP-43 homozygous and heterozygous cells, suggesting a more complex signalling network associated with TDP-43 genotypes and expression level which warrants further study. Overall, our data using cell models expressing the ALS/FTD disease-causing RNA-binding deficient TDP-43 mutations at endogenous levels show a robust impact on transcriptomic profiles at the whole gene and transcript isoform level that compromise neuronal differentiation and processing, providing further insights on TDP-43-mediated neurodegeneration.

Overview

CoChat Summary

TL;DR

CRISPR/Cas9 knock-in of the ALS/FTD-associated RNA-binding-deficient TDP-43 mutants K181E and K263E in SH-SY5Y cells caused transcriptomic and isoform dysregulation, especially in neuronal and synaptic pathways. K181E homozygous and heterozygous cells showed opposing expression patterns, with functional consequences for neuronal differentiation and neurite growth.

Key findings

  • K181E-TDP-43 cells showed 233 differentially expressed genes (DEGs) in homozygous and 167 in heterozygous cells versus wild-type control (q<0.1), while 997 genes differed significantly between K181E homozygous and heterozygous cells (q<0.05).
  • Neuronal/synaptic genes were down-regulated in K181E homozygous cells but up-regulated in K181E heterozygous cells, including known TDP-43 targets STMN2, UNC13A and NPTX2; K263E cells showed no significant DEGs in the undifferentiated state.
  • Isoform switching analysis identified ~7000 significant isoform changes in K181E homozygous and ~400 in K181E heterozygous cells versus wild-type (q<0.05), and ~10,000 between K181E homozygous and heterozygous cells; K181E homozygous cells showed a complete switch from canonical DCTN1-228 to DCTN1-203.
  • Functionally, K181E homozygous cells had reduced MAP2 staining and reduced neurite length, whereas K181E heterozygous cells showed increased MAP2 staining and longer neurites in the undifferentiated condition; K263E cells showed differentiation deficits after differentiation began.

Methods

  • CRISPR/Cas9 nucleofection with gRNA and HDR ssODN was used to introduce K181E or K263E into TARDBP in SH-SY5Y cells; homozygous and heterozygous clones were validated by Sanger sequencing, TARDBP cDNA integrity, Poldip3 splicing, TDP-43 immunofluorescence and cleaved caspase-3 viability assays.
  • Bulk RNA-seq was performed on three independent RNA extractions per CRISPR clone and wild-type SH-SY5Y cells; libraries were poly(A)-selected and sequenced on NovaSeq 6000 (2x150-bp reads, minimum 30 million read pairs per sample), with analysis by kallisto v0.48, tximport, sleuth, fgsea/MSigDB and IsoformSwitchAnalyzeR.
  • SH-SY5Y differentiation used retinoic acid followed by BDNF; immunofluorescence for MAP2 and beta-III-tubulin, RT-PCR for MAP2 and selected genes, and neurite tracing with NeuronJ on MAP2-stained cells (minimum 30 cells across three repeats) were used for functional validation.

Limitations

  • Stated: the extent of disruption correlating with ageing and subsequent challenges still needs further investigation; how neurodevelopmental and neurodegenerative links may develop is not understood; no overt nuclear aggregates were seen at endogenous expression, possibly due to lack of challenge or insufficient expression to drive aggregation.
  • Evident: all experiments are in the SH-SY5Y neuroblastoma cell line in vitro, not patient tissue or in vivo models; K263E showed no significant DEGs in the undifferentiated state, so transcriptomic conclusions are largely driven by K181E; only two RNA-binding-deficient TDP-43 mutations were studied.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/hmg/ddaf111

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC-BY · From the PDF
Image 2
CC-BY · From the PDF
Image 3
CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
Image 6
CC-BY · From the PDF
Image 7
CC-BY · From the PDF
Image 8
CC-BY · From the PDF
Image 9
CC-BY · From the PDF
Image 10
CC-BY · From the PDF
Image 11
CC-BY · From the PDF
Image 12
CC-BY · From the PDF
Image 13
CC-BY · From the PDF
Image 14
CC-BY · From the PDF
Image 15
CC-BY · From the PDF

Verification

Claims the paper makes

0 Valid · 1 Not valid · 44 Not checked · 73 Own results and interpretations

51 more claims

Create a free account to see all 118 claims and to verify the 66 references still open.

See all claims — free account
  • It may state two separate claims as one. 53
  • Probably not a substantial claim. 23

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 100 references

Research works printed but not linked: 4

  1. Mulligan, M.R. and Bicknell, L.S. (2023) The molecular genetics of nELAVL in brain development and disease. European Journal of Human Genetics, 31, 1209-1217.
  2. Basha, M.R., Wei, W., Bakheet, S.A., Benitez, N., Siddiqi, H.K., Ge, Y.W., Lahiri, D.K. and Zawia, N.H. (2005) The fetal basis of amyloidogenesis: Exposure to lead and latent overexpression of amyloid precursor protein and β-amyloid in the aging brain. Journal of Neuroscience, 25, 823-829.
  3. Stillman, B. and Stewart, D. (2007) Regulatory RNAs. Cold Spring Harbor Laboratory Press, 978, 313-320.
  4. Andrews, S. (2019) FastQC: A quality control tool for high throughput sequence data. FastQC: A quality control tool for high throughput sequence data.

Cited by

Metadata

Authors
Magarotto, M., Gawne, R. T., Vilkaite, G., Beltrami, M., Mason, A. S., & Chen, H.-J.
Affiliations
University of York (GB)
Corresponding author
Chen, Han-Jou
Venue
Human Molecular Genetics
Published
2025-06-30
Volume
34
Issue
17
Pages
1480-1494
ISSN
  • 0964-6906 (ISSN-L)
  • 1460-2083
OpenAlex
W4411927652
Cited by
5
References
100
Citations by year
2026: 4 · 2025: 1
FWCI
2.20
Type
journal article
Language
en
Open access
Locations
  • Human Molecular Genetics (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
Funders
  • British Heart Foundation and Diabetes UK (SBF006\1088)
  • ASM’s York Against Cancer
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
TDP-43, amyotrophic lateral sclerosis, frontotemporal dementia, familial mutation, transcriptome dysregulation, neuronal differentiation, synaptic dysfunction, neurite morphology, neurodegeneration, SH-SY5Y cells, CRISPR/Cas9 knock-in
MeSH terms
Amyotrophic Lateral Sclerosis, Cell Differentiation, DNA-Binding Proteins, Humans, Mutation, Neurons, Synapses, RNA-Binding Proteins, Cell Line, Tumor, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.